Frontlight ResearchEarly access
Active, not recruitingNo phase
A Study of Stapokibart Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Key facts
- Who runs it
- Chengdu Kangnuoxing Biopharma,Inc.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 600 people, planned
- Started
- 29 May 2026
- Expected to end
- Feb 2028
- Type of study
- Observational
- Treatments tested
- Stapokibart
- Record updated
- 5 June 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Participants aged 18 years or older at the time of informed consent and provide voluntary informed consent to participate in the study before inclusion in the study
- Physician decision to treat the participant with Stapokibart Injection for CRSwNP (according to the China-specific prescribing information) made prior to and independently of the participant's participation in the study
Who cannot take part
- Known history of allergic reaction to Stapokibart Injection
- Participants with hematologic malignancies
- Any condition that, in the opinion of the Investigator, may interfere with the participant's ability to participate in the study
- Participants currently or plan participating in any interventional clinical trial
- Women with pregnant
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is a open label, prospective study to evaluate the safety of Stapokibart Injection in subjects with CRSwNP.
The group in the trial
- Group 1
Treatment: Stapokibart
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective Study of Stapokibart Injection in Patients With CRSwNP
- Record updated
- 5 June 2026